Loading...
Loading...
ACXP| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 5,114.6K |
| Operating I/L | -5,114.6K |
| Other Income/Expense | 0.0K |
| Interest Income | 0.0K |
| Pretax | -5,114.6K |
| Income Tax Expense | -5.1K |
| Net Income/Loss | -5,114.6K |
Acurx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company specializing in the development of antibiotics to address bacterial infections. Their lead antibiotic candidate, ibezapolstat, has completed Phase II clinical trials for the treatment of clostridium difficile infections. Additionally, the company is working on ACX-375C, an oral and parenteral treatment targeting gram-positive bacteria, including resistant strains such as methicillin-resistant staphylococcus aureus and vancomycin-resistant enterococcus. Acurx Pharmaceuticals, Inc. generates revenue through the development and potential commercialization of these antibiotic treatments.
